More Articles

Strengths and weaknesses of developing generic medicines markets Reports | Posted 30/04/2010

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and M...

Recommendations for developing generic medicines markets Reports | Posted 28/04/2010

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and M...

Strengths and weaknesses of developing mature medicines markets Reports | Posted 28/04/2010

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and M...

Recommendations for mature generic medicines markets Reports | Posted 23/04/2010

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and M...

Overview of the Sustaining Generic Medicines Markets in Europe Reports | Posted 23/04/2010

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and M...

IMS Health Top 20 pharmaceutical companies 2009 Pharma News | Posted 23/04/2010

The 2009 list of the top 20 pharmaceutical companies, ranked by IMS Health according to global prescription drug sales for the 12 months up to September 2009, shows that Teva, Novo Nordisk and Boeh...

Include health economics in development of biosimilars Biosimilars/Research | Posted 15/04/2010

The early inclusion of health economics in the process of developing biopharmaceuticals and biosimilars is imperative with a view to demonstrating their relative (cost) effectiveness and informing...

Health Canada issues finalised guidance on biosimilars Biosimilars/News | Posted 13/04/2010

Health Canada has released the finalised version of its Guidance Document on the approval of Subsequent Entry Biologics (SEBs), which is effective as of 5 March 2010.